Proliant Biologicals Opens New Zealand Facility

BPI Contributor

February 13, 2016

1 Min Read
BioProcess International logo in a gray background | BioProcess International

Proliant Biologicals is proud to announce the opening of its New Zealand Bovine Serum Albumin (BSA) manufacturing facility. The facility is located on the North Island of New Zealand, in Feilding.

The facility was designed and constructed to replicate the “Closed Loop” system, developed and instituted in Proliant’s U.S. facility located in Boone, Iowa. The equipment design and installation was done to functionally duplicate the systems in the U.S. facility, with critical processing systems coming from the same vendors used for U.S. installations.

To maintain consistency, the New Zealand operation has the same vertically integrated raw material to finished product control that is used in the U.S. In regards to raw material supply, Proliant has come to terms on a long term supply agreement with the largest bovine packing company in New Zealand, Silver Fern Farms. As part of this agreement, Proliant is in control of all processes used in blood collection and maintains ownership of all processing equipment for separation of the blood to plasma, at each of the packing facilities used for collection.

With the opening of the Feilding facility, Proliant has significantly increased manufacturing capacity while mitigating risk and opening the ability to supply to markets that are closed to US bovine products.

For more information on the Feilding facility and Proliant Biologicals, please visit www.proliantbiologicals.com.

You May Also Like